Chronic myeloid leukaemia (CML) is primarily treated using imatinib mesylate, a tyrosine kinase inhibitor (TKI) targeting the BCR::ABL1 oncoprotein. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.